Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multicenter Open-Label Extension Study to Assess Long-Term Safety of PF-00547659 in Subjects With Crohn’s Disease (OPERA II)

    Summary
    EudraCT number
    2010-024638-48
    Trial protocol
    SK   BE   SE   AT   PT   DE   NO   NL   ES   PL   BG   Outside EU/EEA  
    Global end of trial date
    27 Jul 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    11 Aug 2017
    First version publication date
    11 Aug 2017
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    A7281007
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01298492
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Shire
    Sponsor organisation address
    300 Shire Way, Lexington, MA, United States, 02421
    Public contact
    Study Physician, Shire, 1 866-842-5335,
    Scientific contact
    Study Physician, Shire, 1 866-842-5335,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    27 Jul 2016
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Jul 2016
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to monitor the safety and tolerability of PF-00547659 during long-term treatment.
    Protection of trial subjects
    This study was conducted in accordance with current applicable regulations, International Council for Harmonisation (ICH) of Good Clinical Practice, the principles of the Declaration of Helsinki, as well as other applicable local ethical and legal requirements.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    22 Jul 2011
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    6 Months
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Austria: 17
    Country: Number of subjects enrolled
    Belgium: 25
    Country: Number of subjects enrolled
    Canada: 7
    Country: Number of subjects enrolled
    France: 18
    Country: Number of subjects enrolled
    Germany: 24
    Country: Number of subjects enrolled
    Japan: 8
    Country: Number of subjects enrolled
    Korea, Republic of: 9
    Country: Number of subjects enrolled
    Netherlands: 36
    Country: Number of subjects enrolled
    Norway: 5
    Country: Number of subjects enrolled
    Poland: 13
    Country: Number of subjects enrolled
    Serbia: 14
    Country: Number of subjects enrolled
    Slovakia: 8
    Country: Number of subjects enrolled
    South Africa: 4
    Country: Number of subjects enrolled
    Spain: 8
    Country: Number of subjects enrolled
    United States: 72
    Worldwide total number of subjects
    268
    EEA total number of subjects
    154
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    265
    From 65 to 84 years
    3
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 81 centers in Austria, Belgium, Canada, France, Germany, Japan, Netherlands, Norway, Poland, Republic of Korea, Serbia, Slovakia, South Africa, Spain and United States between 22 July 2011 (first subject first visit) and 27 July 2016 (last subject last visit).

    Pre-assignment
    Screening details
    A total of 268 subjects (225 subjects from Feeder Study A7281006 [NCT01276509] and 43 subjects from Feeder Study A7281008 [NCT01387594]) were enrolled and overall 149 subjects completed the study.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    PF-00547659 75 mg
    Arm description
    Subjects received PF-00547659 75 mg subcutaneous injection once in every 4 weeks through Week 72. One time dose escalation to 225 mg subcutaneous injection was allowed after 8 weeks of the study for the subjects who experienced clinical deterioration or unacceptably low level of response to study drug. One time dose de-escalation to 22.5 mg subcutaneous injection due to intolerance or AEs was also allowed after the investigator carefully assessed the status of the subject.
    Arm type
    Experimental

    Investigational medicinal product name
    Product 1
    Investigational medicinal product code
    PF-00547659
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received PF-00547659 75 mg subcutaneous injection once in every 4 weeks through Week 72. One time dose escalation to 225 mg subcutaneous injection was allowed after 8 weeks of the study for the subjects who experienced clinical deterioration or unacceptably low level of response to study drug. One time dose de-escalation to 22.5 mg subcutaneous injection due to intolerance or AEs was also allowed after the investigator carefully assessed the status of the subject.

    Number of subjects in period 1
    PF-00547659 75 mg
    Started
    268
    Completed
    149
    Not completed
    119
         Adverse event, serious fatal
    2
         Withdrawn Due to Pregnancy
    1
         Consent withdrawn by subject
    47
         Insufficient Clinical Response
    22
         Unspecified
    7
         Lost to follow-up
    12
         Adverse Event (Related to Study Drug)
    8
         Adverse Event(Not Related to Study Drug)
    18
         Protocol deviation
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    PF-00547659 75 mg
    Reporting group description
    Subjects received PF-00547659 75 mg subcutaneous injection once in every 4 weeks through Week 72. One time dose escalation to 225 mg subcutaneous injection was allowed after 8 weeks of the study for the subjects who experienced clinical deterioration or unacceptably low level of response to study drug. One time dose de-escalation to 22.5 mg subcutaneous injection due to intolerance or AEs was also allowed after the investigator carefully assessed the status of the subject.

    Reporting group values
    PF-00547659 75 mg Total
    Number of subjects
    268
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    36.5 ( 11.7 ) -
    Gender categorical
    Units: Subjects
        Female
    151 151
        Male
    117 117

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    PF-00547659 75 mg
    Reporting group description
    Subjects received PF-00547659 75 mg subcutaneous injection once in every 4 weeks through Week 72. One time dose escalation to 225 mg subcutaneous injection was allowed after 8 weeks of the study for the subjects who experienced clinical deterioration or unacceptably low level of response to study drug. One time dose de-escalation to 22.5 mg subcutaneous injection due to intolerance or AEs was also allowed after the investigator carefully assessed the status of the subject.

    Primary: Number of Subjects with On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Number of Subjects with On-Treatment Adverse Events (AEs), AEs Led to Withdrawal, and Serious Adverse Events (SAEs) [1]
    End point description
    AEs included adverse drug reactions, illnesses with onset during the study, exacerbation of previous illnesses, clinically significant changes in physical examination findings and abnormal objective test findings (electrocardiogram (ECG), laboratory). An SAE was defined as any AE at any dose that resulted in death; was life threatening (immediate risk of death); required in-subject hospitalization or prolongation of existing hospitalization; resulted in a persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); or resulted in congenital anomaly/birth defect. The modified intent-to-treat (mITT) population included all enrolled subjects who received at least 1 dose of investigational product was analysed for this end point.
    End point type
    Primary
    End point timeframe
    From start of study treatment up to Week 72 (Treatment Period)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistics were done, no inferential statistical analyses were performed.
    End point values
    PF-00547659 75 mg
    Number of subjects analysed
    268
    Units: subject
        Subjects With AEs
    249
        Subjects With AEs Led to Withdrawal
    53
        Subjects With SAEs
    80
    No statistical analyses for this end point

    Secondary: Number of Subjects with Positive Anti-Drug (PF-00547659) Antibodies

    Close Top of page
    End point title
    Number of Subjects with Positive Anti-Drug (PF-00547659) Antibodies
    End point description
    Positive Anti-Drug Antibodies (ADA) result was defined as ADA titre value greater than or equal to (>=) 4.64 at at least one of the time points. The modified intent-to-treat (mITT) population included all enrolled subjects who received at least 1 dose of investigational product was analysed for this end point.
    End point type
    Secondary
    End point timeframe
    Baseline up to Week 96
    End point values
    PF-00547659 75 mg
    Number of subjects analysed
    268
    Units: subject
        Subjects
    63
    No statistical analyses for this end point

    Secondary: Serum Trough Concentrations of PF-00547659 Versus Time

    Close Top of page
    End point title
    Serum Trough Concentrations of PF-00547659 Versus Time
    End point description
    Serum trough concentrations of PF-00547659 were analyzed using population Pharmacokinetic (PK) methodology. The PK population included all enrolled subjects who received at least 1 dose of investigational product and had data on at least 1 PK concentration was analysed for this end point. Here "n" represents the number of subjects evaluable for this end point.
    End point type
    Secondary
    End point timeframe
    Week 4,8,12,16,20,24,28,32,36,40,44,48,52,56,60,64,68,72,76,80,84,88,92,96
    End point values
    PF-00547659 75 mg
    Number of subjects analysed
    260
    Units: nanogram per milliliter (ng/mL)
    arithmetic mean (standard deviation)
        Week 4 (n=226)
    6673 ( 6634.2 )
        Week 8 (n=222)
    6064 ( 4455.3 )
        Week 12 (n=201)
    8040 ( 6293.1 )
        Week 16 (n=188)
    9563 ( 7285.4 )
        Week 20 (n=186)
    10400 ( 8438.6 )
        Week 24 (n=172)
    10450 ( 7934.6 )
        Week 28 (n=162)
    10780 ( 9211 )
        Week 32 (n=165)
    11920 ( 10675 )
        Week 36 (n=164)
    12460 ( 9717.1 )
        Week 40 (n=152)
    12570 ( 10077 )
        Week 44 (n=149)
    12960 ( 10999 )
        Week 48 (n=148)
    13170 ( 11108 )
        Week 52 (n=144)
    13560 ( 11388 )
        Week 56 (n=134)
    13930 ( 11191 )
        Week 60 (n=131)
    14130 ( 11095 )
        Week 64 (n=127)
    14360 ( 11290 )
        Week 68 (n=120)
    14990 ( 12883 )
        Week 72 (n=114)
    13910 ( 10554 )
        Week 76 (n=173)
    10520 ( 10082 )
        Week 80 (n=170)
    3555 ( 5339.8 )
        Week 84 (n=149)
    1129 ( 2634.7 )
        Week 88 (n=145)
    403.8 ( 1522.6 )
        Week 92 (n=136)
    154.2 ( 1001.9 )
        Week 96 (n=145)
    54.73 ( 487.07 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From Start of Study Treatment up to Safety Follow up (Week 96)
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.0
    Reporting groups
    Reporting group title
    PF-00547659 75 mg
    Reporting group description
    Subjects received PF-00547659 75 mg subcutaneous injection once in every 4 weeks through Week 72. One time dose escalation to 225 mg subcutaneous injection was allowed after 8 weeks of the study for the subjects who experienced clinical deterioration or unacceptably low level of response to study drug. One time dose de-escalation to 22.5 mg subcutaneous injection due to intolerance or AEs was also allowed after the investigator carefully assessed the status of the subject.

    Serious adverse events
    PF-00547659 75 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    118 / 268 (44.03%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Colon cancer
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Metastatic neoplasm
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Renal cancer
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Surgical and medical procedures
    Benign breast lump removal
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    General physical health deterioration
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyrexia
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Female genital tract fistula
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Menorrhagia
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Perineal fistula
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pleural effusion
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Investigations
    Blood creatine phosphokinase mm increased
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Haematocrit decreased
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Anastomotic leak
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Fracture
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal stoma complication
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Humerus fracture
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Postoperative ileus
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Stomal hernia
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Upper limb fracture
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Wound dehiscence
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Coronary artery disease
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Headache
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Intracranial venous sinus thrombosis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Visual impairment
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal hernia obstructive
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal pain
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Anal fistula
         subjects affected / exposed
    7 / 268 (2.61%)
         occurrences causally related to treatment / all
    0 / 7
         deaths causally related to treatment / all
    0 / 0
    Anal stenosis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Colitis ulcerative
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Crohn's disease
         subjects affected / exposed
    44 / 268 (16.42%)
         occurrences causally related to treatment / all
    1 / 51
         deaths causally related to treatment / all
    0 / 0
    Duodenitis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Enterocutaneous fistula
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorder
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ileal stenosis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ileus
         subjects affected / exposed
    4 / 268 (1.49%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Intestinal fistula
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intestinal haemorrhage
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Large intestinal stenosis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Melaena
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nausea
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancreatitis acute
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    4 / 268 (1.49%)
         occurrences causally related to treatment / all
    0 / 11
         deaths causally related to treatment / all
    0 / 0
    Vomiting
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cholecystitis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholecystitis acute
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hepatic cyst
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Skin and subcutaneous tissue disorders
    Pyoderma gangrenosum
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Bladder dysfunction
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nephrolithiasis
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ureterolithiasis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinoma
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Endocrine disorders
    Adrenocortical insufficiency acute
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arthritis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Arthritis enteropathic
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Muscle spasms
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Muscular weakness
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spinal column stenosis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spinal osteoarthritis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Abdominal abscess
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Abdominal wall abscess
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Abscess intestinal
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abscess neck
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anal abscess
         subjects affected / exposed
    10 / 268 (3.73%)
         occurrences causally related to treatment / all
    1 / 10
         deaths causally related to treatment / all
    0 / 0
    Clostridium difficile infection
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    Device related infection
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis viral
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Liver abscess
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pelvic abscess
         subjects affected / exposed
    2 / 268 (0.75%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    Perirectal abscess
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Peritonitis
         subjects affected / exposed
    3 / 268 (1.12%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    4 / 268 (1.49%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Postoperative abscess
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Rotavirus infection
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Splenic abscess
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tonsillitis
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vulval abscess
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Fluid retention
         subjects affected / exposed
    1 / 268 (0.37%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    PF-00547659 75 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    206 / 268 (76.87%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    35 / 268 (13.06%)
         occurrences all number
    45
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    15 / 268 (5.60%)
         occurrences all number
    20
    Fatigue
         subjects affected / exposed
    20 / 268 (7.46%)
         occurrences all number
    23
    Pyrexia
         subjects affected / exposed
    27 / 268 (10.07%)
         occurrences all number
    36
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    49 / 268 (18.28%)
         occurrences all number
    59
    Anal fissure
         subjects affected / exposed
    14 / 268 (5.22%)
         occurrences all number
    14
    Aphthous ulcer
         subjects affected / exposed
    14 / 268 (5.22%)
         occurrences all number
    18
    Crohn's disease
         subjects affected / exposed
    79 / 268 (29.48%)
         occurrences all number
    111
    Diarrhoea
         subjects affected / exposed
    24 / 268 (8.96%)
         occurrences all number
    38
    Nausea
         subjects affected / exposed
    32 / 268 (11.94%)
         occurrences all number
    44
    Vomiting
         subjects affected / exposed
    23 / 268 (8.58%)
         occurrences all number
    34
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    83 / 268 (30.97%)
         occurrences all number
    113
    Back pain
         subjects affected / exposed
    28 / 268 (10.45%)
         occurrences all number
    30
    Infections and infestations
    Anal abscess
         subjects affected / exposed
    14 / 268 (5.22%)
         occurrences all number
    16
    Bronchitis
         subjects affected / exposed
    20 / 268 (7.46%)
         occurrences all number
    26
    Gastroenteritis
         subjects affected / exposed
    19 / 268 (7.09%)
         occurrences all number
    22
    Influenza
         subjects affected / exposed
    18 / 268 (6.72%)
         occurrences all number
    19
    Nasopharyngitis
         subjects affected / exposed
    54 / 268 (20.15%)
         occurrences all number
    93
    Pharyngitis
         subjects affected / exposed
    15 / 268 (5.60%)
         occurrences all number
    18
    Upper respiratory tract infection
         subjects affected / exposed
    20 / 268 (7.46%)
         occurrences all number
    25
    Urinary tract infection
         subjects affected / exposed
    19 / 268 (7.09%)
         occurrences all number
    28

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    15 Feb 2011
    Subjects were required to discontinue concomitant immunosuppressants prior to entering the open-label extension (OLE) study; interim analysis was added to study with statistical analysis modified accordingly.
    17 May 2011
    Included addition of footnotes to the Schedule of Activities to clarify which procedures would be carried forward from A7281006 (2010-023437-30) and A7281008 (2011-001443-74) Week 12 and not repeated. Addition of risk-benefit section; creation of section on Dosing to better describe the dose escalation and dose discontinuation criteria; update to reporting period for AEs; update of injection site monitoring instructions.
    18 Jul 2011
    Title of study updated; clarification to baseline procedures section and also other study visits in the Study Procedures section to specify that repeat NTproBNP, echocardiogram, and cardiology consultation should be performed for specified elevations in NTproBNP and that data were to be reviewed if applicable.
    23 Apr 2012
    Updates to protocol summary, study design, study design schematic, early withdrawal from OLE treatment for responders that relapse, minor administrative changes/corrections.
    25 Jun 2012
    Addition of Schedule of Activities for subjects enrolled in Japan and estimation of PK parameters for subjects enrolled in Japan.
    01 Aug 2012
    Addition of Appendix 8: Appendix 8 consisted of a version of the protocol to be implemented in Japan to accommodate specific requirements from the Pharmaceuticals and Medical Devices Agency.
    19 Feb 2013
    Revision of interim analysis section for clarification and revisions to PK analysis section and exploratory pharmacodynamics analysis section; revision to Data Monitoring Committee to indicate that the interim analysis results would be reviewed by the Data Monitoring Committee; added units from International System of Units for NTproBNP levels; addition of Simple Endoscopic Score for Crohn’s Disease (SES-CD).
    09 Dec 2015
    Removal of 18-month telephone call follow-up period and corresponding updates to protocol sections where applicable; addition of note for clarification of baseline for neurological assessments where applicable; and updates where applicable to be consistent with Pfizer standards.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 04:14:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA